Personalis, Inc. filings document regulatory disclosures for a Nasdaq-listed precision oncology genomics company focused on sequencing, data analysis and cancer monitoring tests. Form 8-K reports cover quarterly and annual operating results, clinical test revenue, business highlights, financial guidance and material events involving NeXT Personal and related reimbursement decisions.
The company’s filings also disclose Medicare coverage and rate determinations for NeXT Personal breast and lung cancer surveillance tests, officer appointments and related compensation arrangements, and the registered common stock traded under PSNL. Proxy materials cover board matters, shareholder voting items, executive compensation and governance disclosures for the public company.
Personalis, Inc. reported new equity awards to SVP and Chief Legal Officer Stephen Michael Moore. He received stock options for 168,750 shares of common stock at an exercise price of $6.72 per share, and 28,125 shares of common stock as restricted stock units.
The RSUs vest in six equal semi-annual installments starting on September 15, 2026. The stock options vest in 36 equal monthly installments beginning on April 15, 2026. After these grants, Moore directly holds 92,325 shares of common stock.
Personalis, Inc. Chief Executive Officer Christopher M. Hall reported equity awards consisting of new stock options and restricted stock units. He was granted options to buy 525,000 shares of common stock at an exercise price of 6.7200 per share, vesting in 36 equal monthly installments beginning on April 15, 2026, and expiring on March 15, 2036.
Hall also received 87,500 shares of common stock represented by restricted stock units, which vest in six equal semi-annual installments starting on September 15, 2026. Following the grant, his directly held common stock position reported in this filing is 235,986 shares. These are compensation-related awards rather than open-market purchases.
Personalis, Inc. reported that President and CMO Richard Chen received new equity awards. He was granted stock options for 281,250 shares of common stock at an exercise price of $6.72 per share, vesting in 36 equal monthly installments starting on April 15, 2026.
Chen also received 46,875 restricted stock units, each representing one share of common stock, vesting in six equal semi-annual installments beginning on September 15, 2026. Following these awards, he directly holds 173,880 shares of common stock.
Personalis, Inc. appointed Richard Chen as President, adding to his roles as Executive Vice President, R&D, and Chief Medical Officer. Christopher Hall previously served as President and remains Chief Executive Officer.
Chen’s annual base salary will increase to $570,000 effective April 1, 2026, with a performance bonus target set at 70% of his then-current base salary. On March 15, 2026, he will receive an option to purchase 37,500 shares of common stock at the March 13, 2026 closing price, vesting in equal monthly installments over 36 months, and a restricted stock unit award covering 6,250 shares, vesting over time starting six months after the grant date, in each case subject to continued service under the company’s 2019 Equity Incentive Plan.
Personalis, Inc. provides advanced cancer genomic testing services used by physicians and drug developers for minimal residual disease detection, recurrence monitoring, and therapy selection. Key offerings include NeXT Personal Dx and NeXT Dx, supported by a CLIA-certified, CAP-accredited lab in Fremont, California.
The company recently secured Medicare coverage for NeXT Personal Dx in Stage II–III breast cancer (effective October 7, 2025) and Stage I–III non-small cell lung cancer (effective January 9, 2026), plus earlier coverage for its NeXT Dx comprehensive genomic profiling test. Despite this progress, Personalis reported a net loss of $81.3 million in 2025 and an accumulated deficit of $631.3 million, and remains dependent on a concentrated customer base, notably Moderna and the VA Million Veteran Program.
Personalis, Inc. reported fourth quarter and full year 2025 results and issued 2026 guidance, highlighting rapid growth in its clinical testing business alongside continued losses. Full year 2025 revenue was $69.6 million, down from $84.6 million, with a net loss of $81.3 million. However, clinical test volume surged nearly 400% to 16,233 tests, and Q4 clinical test revenue rose to $0.9 million from $0.2 million. The company ended 2025 with about $240 million in cash, cash equivalents and short-term investments, including $109 million of ATM proceeds. For 2026, Personalis guides to revenue of $78–$80 million, clinical revenue of $10–$11 million on 43,000–45,000 tests, and expects a net loss of about $105 million and cash usage of about $100 million as it invests behind 5x projected clinical revenue growth.
Personalis, Inc. executive Aaron Tachibana, the company’s CFO and COO, reported an acquisition of derivative securities through equity compensation. On February 23, he became entitled to 15,000 stock options at an exercise price of $0.00 per share, held as direct ownership.
According to the disclosure, this amount reflects the vesting of a performance stock option originally granted on March 15, 2024, after a specified reimbursement milestone was satisfied. The filing records this as a grant or award-type acquisition rather than an open-market purchase or sale of Personalis common stock.
Personalis, Inc. reported that Chief Medical Officer and EVP Richard Chen acquired 15,000 stock options through the vesting of a performance-based award. The options relate to a performance stock option originally granted on March 15, 2024, which vested after a specified reimbursement milestone was achieved, bringing his directly held derivative position to 15,000 options.
Personalis, Inc. reported an insider equity transaction for Stephen Michael Moore, its SVP and Chief Legal Officer. He acquired 8,333 stock options, recorded as a grant or award at a reported price of $0.0000 per option.
According to the footnote, this reflects the vesting of a performance stock option originally granted on March 15, 2024, after a specified reimbursement milestone was satisfied. Following this transaction, Moore held a total of 8,333 stock options directly.
Personalis, Inc. reported that President and CEO Christopher M. Hall acquired rights to 33,333 shares through the vesting of a performance stock option. The option tranche vested on February 23, 2026 after the company met a specified reimbursement milestone tied to the original grant made on March 15, 2024.
The transaction is coded as a grant or award acquisition, with no cash paid per option at vesting. Following this vesting event, Hall holds 33,333 stock options related to this performance-based award as direct ownership.